A322970 Stock Overview
Moogene Medi Co., Ltd. develops gene therapies based on its proprietary gene-editing platform technology.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Moogene Medi Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩2,580.00 |
52 Week High | ₩4,015.00 |
52 Week Low | ₩2,205.00 |
Beta | 0 |
1 Month Change | -4.62% |
3 Month Change | -8.83% |
1 Year Change | -25.86% |
3 Year Change | -50.67% |
5 Year Change | n/a |
Change since IPO | -56.64% |
Recent News & Updates
Recent updates
Shareholder Returns
A322970 | KR Biotechs | KR Market | |
---|---|---|---|
7D | 4.5% | 4.0% | 3.2% |
1Y | -25.9% | 22.1% | 13.4% |
Return vs Industry: A322970 underperformed the KR Biotechs industry which returned 22.1% over the past year.
Return vs Market: A322970 underperformed the KR Market which returned 13.4% over the past year.
Price Volatility
A322970 volatility | |
---|---|
A322970 Average Weekly Movement | 12.0% |
Biotechs Industry Average Movement | 8.0% |
Market Average Movement | 5.2% |
10% most volatile stocks in KR Market | 12.0% |
10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A322970 has not had significant price volatility in the past 3 months.
Volatility Over Time: A322970's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | n/a | https://www.moogene.com |
Moogene Medi Co., Ltd. develops gene therapies based on its proprietary gene-editing platform technology. The company’s product portfolio comprises MG-001, which is in Phase I clinical trials to treat colon cancer; MG-002 that is in preclinical stage for use in the treatment of pancreatic cancer; and MG-003, which is in preclinical stage for use in the treatment of diabetes mellitus. Its research stage products include MG-004 for treating hair loss and MG-005 for use in the treatment of Crohn's disease.
Moogene Medi Co., Ltd. Fundamentals Summary
A322970 fundamental statistics | |
---|---|
Market cap | ₩25.84b |
Earnings (TTM) | ₩0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A322970 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A322970 income statement (TTM) | |
---|---|
Revenue | ₩0 |
Cost of Revenue | ₩0 |
Gross Profit | ₩0 |
Other Expenses | ₩0 |
Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did A322970 perform over the long term?
See historical performance and comparison